Can Fite BioPharma Ltd (CANF)

[Spideyboy]

Hi,

Been looking at this one for over a year now and seems like it might be interesting to get into.

From what I understand, this is looking like a replacement for MTX but with better safety profile and potential higher efficacy. MTX was also used for a plethora of diverse indications, and CANF is based on different formula of the same target A3AR is hoping for the same thing.

Looking at the events coming this year, the key one seems to be the RA indication.

Concerns I have at the moment is from the company presentation from just last month they had 15 million in the bank, of which 5 million is going into the RA Phase III ACRobat trial. Leaving just 10 million in the bank for everything else.

Do we know how long CANF estimates the ACRobat trial to last?

They appear to have a low cash burn, about 6 million per year, but with the added Psoriasis phase III and NASH Phase II to also begin this year, do we not think they will burn through the remaining 10 million by early Q4 2017?

I see they have some partnerships but with low up-front payments.

Effectively do we expect their low cash reserves to create need for more dilution by Q4 2017?

Thanks!